EN DE
Watch Lyell Immunopharma Inc for free: we tell you when fair value or trend changes.
Data-driven stock valuation

Lyell Immunopharma Inc (LYEL) fair value: what the stock is really worth

As of Nov 6, 2026: fair value (intrinsic value) of Lyell Immunopharma Inc stock $5.87, price $14.86, that is 60.5% below the price, quality 22 out of 100. Rating: strongly overvalued. Calculated from audited financials with one of our 26 valuation models and 37 quality factors, updated daily.

  1. Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free

Healthcare US

LI Lyell Immunopharma Inc logo Thin data Nov 8, 2026

Lyell Immunopharma Inc

LYEL · US
Very expensive, weak quality

Our calculation puts a fair price 61% below what the stock costs today.

Insiders sold $255,242 (6M)
Revenue last quarter 50% below a year ago.
Fair value $5.87 · Strongly overvalued
Quality 22/100
Weak Growth (revenue 5y −65.9 %/yr in USD)
Negative free cash flow
Trails peers (1/6)
Narrow moat 6/100 · thin data
Thin data
⚠ Dilution
Watch Lyell Immunopharma Inc for free: we tell you when fair value or trend changes. Watch for free

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

$359.00 $7.51 Fair Value $5.87 Aug 2021 Nov 2026

White line = price, green steps = our fair value per fiscal year. As of Nov 8, 2026.

How to read this chart

60‑month range $7.51 – $359.00 · fair‑value band $3.87 – $7.34 · the $14.86 price screens above the $5.87 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 8, 2026.

Follow Lyell Immunopharma in your weekly email

Every Wednesday you see whether Lyell Immunopharma is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Lyell Immunopharma, Inc., a clinical-stage cell therapy company, develops chimeric antigen receptor (CAR) T-cell product candidates for patients with hematologic malignancies and solid tumors.

Show moreShow less

The company's lead product candidate include rondecabtagene autoleucel, an autologous dual-targeting CD19/CD20 CAR T-cell therapy in development, which is in pivotal PiNACLE trial in the 3L+ setting and in a Phase 1/2 clinical trial in the 2L setting, as well as a second pivotal trial, PiNACLE-H2H, which is a Phase 3 head-to-head CAR T cell therapy randomized controlled trial of ronde-cel for LBCL in the 2L setting for the treatment of large B-cell lymphoma; and LYL273, a GCC-targeted CAR T-cell product candidate enhanced with CD19 CAR expression and controlled cytokine release designed to improve CAR T-cell expansion, immune cell infiltration, and cancer cell killing in the hostile solid tumor microenvironment, which is in Phase 1 clinical trial for the treatment of refractory metastatic colorectal cancer.

The company develops therapies using various approaches, such as c-Jun overexpression and NR4A3 gene knockout, to endow functional resistance to exhaustion; Epi-R to generate population of stem-like T cells with reduced exhaustion and improved proliferation and antitumor activity; and CD62L positive enrichment to generate CAR T cells with enhanced antitumor activity.

Lyell Immunopharma, Inc. was incorporated in 2018 and is headquartered in South San Francisco, California.

Stock analysis

Lyell Immunopharma Inc (LYEL) currently trades at $14.86, while our model-based Fair Value estimate is $5.87, 61% below the price, so the stock looks overvalued today.

Show more

Valuation

How firm this estimate is: it rests on 1 models at a data quality of 96/100, which puts the data coverage at low.

Scenario range: $3.87 (bear) to $7.34 (bull), the price of $14.86 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 22/100 (below-average quality), in the Healthcare sector.

Weak Growth: Revenue is shrinking: the last year, the last three and the last five years are all negative.

Lyell Immunopharma Inc reported revenue of $36.0K in FY2025 versus $10.7M in FY2021, a compound −75.9%/yr. Reported net income was −$274M in FY2025.

Key figures

Market cap $378M Small · EPS (TTM) $−12.86 · Return on equity −93.3% · Return on assets (EBIT) −41.0% (5-year average) · Operating margin −1,183,425% · Revenue (TTM) $27.0K · Revenue growth (YoY) −50.0% · Free cash flow −$151M.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 6 out of 100 (low confidence).

What moves the price

The share trades about 62% below its 52-week high and 98% above its 52-week low, currently below its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at 10% fair-value upside, at −61%, LYEL screens richer than that median.

Fair Value models

Bear $3.87 Fair Value $5.87 Bull $7.34
Price $14.86 · Downside -60.5%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds. Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Best data coverage
NCAV (Graham) $4.55 $6.90 $8.63 52
All 1 models by family
Asset-Based
NCAV (Graham) $4.55 $6.90 $8.63 52

The fair value above starts from this blend and is adjusted for dilution from new shares.

Open the full fair value analysis →

Quality Score breakdown

Overall quality 22/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 0
How much profit the company makes from its sales and capital
Quality Growth 10
Are margins and returns getting better?
Cashflow 1
Do the profits arrive as real cash?
Financial strength 65
Debt, balance sheet and risk of trouble
Investment 67
Does it invest with discipline instead of growing at any price?
Low Volatility 50
How calm the share price moves, does not count
Price momentum 21
Price momentum of the last 3 to 12 months, does not count
Near the 52-week high 23
Distance to the 52-week high, does not count
New shares 0
Buys back shares or issues new ones?

Open the full quality analysis →

Insider trades

In the last 6 months, 6 officers or directors sold shares worth $255,242 and none bought.

  • BuyARCH Venture Fund XIII, L.P.10% owner2,321,262 shares at $10.77$25.0MNov 4, 2026
  • BuyARCH Venture Partners IX, LLC10% owner2,321,262 shares at $10.77$25.0MNov 4, 2026
  • SaleJarrad Mattieu AguirreChief Medical Officer422 shares at $8.63$3,642Oct 12, 2026
  • SaleDavid ShookChief Medical Officer2× since Jun 10, 2026: 2,477 shares, avg. $12.65$31,339Sep 10, 2026
  • SaleLynn SeelyPresident and CEO, Director6× since Nov 10, 2025: 18,672 shares, avg. $18.91$353,079Aug 21, 2026
  • SaleStephen J. HillChief Operating Officer6× since Nov 10, 2025: 2,607 shares, avg. $19.67$51,291Aug 21, 2026
  • SaleGary K. LeeChief Scientific Officer6× since Nov 10, 2025: 3,674 shares, avg. $19.51$71,693Aug 21, 2026
  • SaleVeronica Sanchez BulisVP, Corporate Controller5× since Nov 10, 2025: 3,403 shares, avg. $28.48$96,910Aug 10, 2026
  • SaleInnovative Cellular Therapeutics Holdings Ltd10% owner2× since Jul 16, 2026: 20 shares, avg. $13.72$274Jul 17, 202610b5-1 plan
  • BuyPaul L Berns10% owner488,090 shares at $25.61$12.5MMar 6, 2026

Plus 1 more entries from the last 12 months.

Plus 4 other filings such as grants, option exercises or tax withholding. They are not market purchases or sales.

Sales are often planned (taxes, diversification, 10b5-1 plans). Purchases with their own money are seen as the stronger sign. For information only: not part of the quality score or Fair Value.

Source: SEC Form 4, as of Nov 6, 2026. All filings at the SEC ↗

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 0/100
Revenue is shrinking: the last year, the last three and the last five years are all negative.
Revenue growth 1 year
−41.0%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−92.5%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−65.9%
Start year 2020 (pandemic)
Revenue growth 6 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−38.4%
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−2,732.6% (2020) → −566,038.9% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed

LYEL screens overvalued: fair value 61% below the price. Compare with Vertex Pharmaceuticals Incorporated →

Compare Lyell Immunopharma Inc with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 558 stocks

Beats the industry median on 1/5 measures
Overall it trails its industry peers.
Valuation
Quality Score 22 · Bottom 25%
Fair Value upside −60.5% · Below median
Profitability
Return on assets −80.7% · Bottom 25%
Growth and dividend
Revenue growth (quarter YoY) −50.0% · Bottom 25%

Valuation Multiplesvs Biotechnology median · lower = cheaper

P/B 1.52× · Cheaper than median

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Biotechnology stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value Compare
Incyte Corporation INCY $119.65 $199.23 +67% vs LYEL
Regeneron Pharmaceuticals, Inc REGN $904.35 $1,275 +41% vs LYEL
Vertex Pharmaceuticals Incorporated VRTX $547.09 $601.80 +10% vs LYEL
Samsung Biologics Co 207940 1,516,000 KRW 1,667,600 KRW +10% vs LYEL
Genmab A/S GMAB kr 3,527 kr 3,880 +10% vs LYEL
WuXi Biologics (Cayman) Inc 2269 HK$47.62 HK$52.38 +10% vs LYEL
argenx SE ARGX $927.21 $908.40 −2% vs LYEL
CSL Limited CSL A$200.77 A$183.04 −9% vs LYEL
Celltrion, Inc 068270 211,000 KRW 74,945 KRW −64% vs LYEL
Royalty Pharma plc RPRX $67.30 $19.01 −72% vs LYEL

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend StocksUndervalued 52-Week Low Stocks

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Free calculator Peter Lynch Fair Value Formula &…Free calculator
Run the numbers yourself: free valuation calculators
DCF CalculatorP/E Ratio CalculatorPEG Ratio CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorIntrinsic ValueIntrinsic vs Extrinsic ValueP/E Ratio by Sector
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Lyell Immunopharma Inc: fair value per Fair Value Calculator

Cite: Fair Value Calculator (2026). "Lyell Immunopharma Inc Fair Value". https://www.fairvalue-calculator.com/stock/LYEL

Frequently asked questions

Is Lyell Immunopharma Inc (LYEL) overvalued or undervalued?
As of Nov 8, 2026, our model estimates a fair value of $5.87 versus a price of $14.86, about 61% lower (overvalued).
What is the fair value of LYEL?
Our model-based fair value for Lyell Immunopharma Inc is $5.87 (as of Nov 8, 2026), built from audited fundamentals. The current price: $14.86.
What is the quality score of LYEL?
Lyell Immunopharma Inc has a Quality Score of 22/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Lyell Immunopharma Inc (LYEL)?
Our model-based price target is the fair value of $5.87 (as of Nov 8, 2026) from 1 valuation models. Cautious scenario $3.87, optimistic scenario $7.34. It is a calculation from audited fundamentals, not an analyst target.
What is the Lyell Immunopharma Inc stock forecast for 2026?
Our models put fair value at $5.87, about 61% lower versus a price of $14.86 (overvalued). Cautious scenario $3.87, optimistic scenario $7.34. The calculation is refreshed regularly with new filings.
What is the revenue of Lyell Immunopharma Inc (LYEL)?
Lyell Immunopharma Inc reported trailing-twelve-month revenue of about $27.0K (latest available figure, as of Nov 8, 2026).
What is the intrinsic value of Lyell Immunopharma Inc (LYEL)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Lyell Immunopharma Inc it is $5.87 per share (as of Nov 8, 2026), against a price of $14.86. It is the blended result of 1 valuation models in 1 family (Asset-Based).
Is Lyell Immunopharma Inc stock overvalued or undervalued in 2026?
As of Nov 8, 2026, LYEL trades above its calculated fair value: price $14.86, fair value $5.87, a gap of about −61% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of LYEL?
No. The price is what the market pays today ($14.86); the fair value is what the company's own numbers justify ($5.87). For Lyell Immunopharma Inc the two are $9.00 per share apart. That gap is exactly why we show both numbers side by side.
How much is Lyell Immunopharma Inc worth?
The market values Lyell Immunopharma Inc at about $378M (market capitalisation, as of Nov 8, 2026). Per share that is $14.86; our models calculate a fair value of $5.87 per share.
What do the bullish and bearish scenarios say about LYEL?
Our models span a range for Lyell Immunopharma Inc: cautious scenario $3.87, base $5.87, optimistic $7.34 per share (as of Nov 8, 2026, price $14.86). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Lyell Immunopharma Inc (LYEL)?
Balance-sheet figures for Lyell Immunopharma Inc (as of Nov 8, 2026): return on equity −93.3%. They feed the Quality Score of 22/100, which measures business quality independently of the share price.
How far is LYEL from its 52-week high?
Lyell Immunopharma Inc trades at $14.86, about 62% below its 52-week high of $38.60 and 98% above the low of $7.51 (as of Nov 6, 2026). Distance from the high says nothing about value: that is what the fair value of $5.87 is for.
Which stocks are comparable to Lyell Immunopharma Inc?
From the same area (Healthcare) we also value Vertex Pharmaceuticals Incorporated, Regeneron Pharmaceuticals, Inc, CSL Limited, argenx SE, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Lyell Immunopharma Inc stock attractive at the current price?
The data as of Nov 8, 2026: price $14.86, calculated fair value $5.87 (−61%), Quality Score 22/100, from 1 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of LYEL calculated?
We run Lyell Immunopharma Inc through 1 models from 1 family: Asset-Based. Every model gets the same audited fundamentals; the fair value of $5.87 builds on their evidence-weighted average, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.3% above its aggregate fair value. Lyell Immunopharma Inc itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Lyell Immunopharma Inc (LYEL)?
The closing price on Nov 6, 2026 was $14.86. Our model-based fair value is $5.87, about 61% lower (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Lyell Immunopharma Inc right now?
The price sits above even our optimistic bull case ($7.34). The favourable scenario is already priced in. Weak quality (22/100) and above fair value at the same time, the margin of safety is missing on both counts. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution. A fairly wide model range ($3.87 to $7.34) leaves room in how you read the outcome.

Key figures of Lyell Immunopharma Inc

How large is the market capitalisation of Lyell Immunopharma Inc (LYEL)?
The market capitalisation of Lyell Immunopharma Inc is $378M. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What are the earnings per share of Lyell Immunopharma Inc (LYEL)?
Earnings per share at Lyell Immunopharma Inc are $−12.86. Earnings per share over the last twelve months: total profit spread across every single share.
What is the return on equity of Lyell Immunopharma Inc (LYEL)?
The return on equity (ROE) of Lyell Immunopharma Inc is −93.3% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Lyell Immunopharma Inc (LYEL)?
On an EBIT basis the return on assets of Lyell Immunopharma Inc is −41.0% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Lyell Immunopharma Inc (LYEL)?
The operating margin of Lyell Immunopharma Inc is −1,183,425% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Lyell Immunopharma Inc (LYEL)?
Revenue at Lyell Immunopharma Inc is growing −50.0% versus a year earlier (3y avg −92.5%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How much free cash flow does Lyell Immunopharma Inc (LYEL) generate?
The free cash flow of Lyell Immunopharma Inc is −$151M (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net cash does Lyell Immunopharma Inc (LYEL) hold?
Lyell Immunopharma Inc holds more cash than debt, $9.2M net (fiscal year 2025). The company holds more cash than debt, a safety cushion.
Free · no account needed

Watch Lyell Immunopharma Inc in the live analysis

One click puts Lyell Immunopharma Inc on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.